Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

The Lancet Oncology

Volumn 10, Issue 3, 2009, Pages 267-277

  Reinholz, Monica M ^a   Bruzek, Amy K ^a   Visscher, Daniel W ^b   Lingle, Wilma L ^a   Schroeder, Matthew J ^a   Perez, Edith A ^c   Jenkins, Robert B ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PROTEIN P53; TRASTUZUMAB; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ANEUSOMY 17; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INVASION; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL TRIAL; DRUG RESPONSE; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; HUMAN; METASTASIS; MONOSOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; ANEUPLOIDY; BREAST TUMOR; DISEASE COURSE; FEMALE; GENETICS; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, P53; HUMANS; PROGNOSIS;

EID: 62849109983     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70063-4     Document Type: Review

References (76)

1. Boveri T. On multipolar mitosis as a means of analysis of the cell nucleus. Develop Biol 35 (1902) 67-90
2. Geleick D., Muller H., Matter A., Torhorst J., and Regenass U. Cytogenetics of breast cancer. Cancer Genet Cytogenet 46 (1990) 217-229
3. Thompson F., Emerson J., Dalton W., et al. Clonal chromosome abnormalities in human breast carcinomas. I. Twenty-eight cases with primary disease. Genes Chromosomes Cancer 7 (1993) 185-193
4. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
5. Yao J., Weremowicz S., Feng B., et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 66 (2006) 4065-4078
6. Nagai M.A., Medeiros A.C., Brentani M.M., et al. Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumors. Oncology 52 (1995) 448-453
7. Shackney S.E., Singh S.G., Yakulis R., et al. Aneuploidy in breast cancer: a fluorescence in situ hybridization study. Cytometry 22 (1995) 282-291
8. Chin S.F., Wang Y., Thorne N.P., et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 26 (2007) 1959-1970
9. Fridlyand J., Snijders A.M., Ylstra B., et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6 (2006) 96
10. Botti C., Pescatore B., Mottolese M., et al. Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. J Am Coll Surg 190 (2000) 530-539
11. Bergamaschi A., Kim Y.H., Wang P., et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45 (2006) 1033-1040
12. Persons D.L., Robinson R.A., Hsu P.H., et al. Chromosome-specific aneusomy in carcinoma of the breast. Clin Cancer Res 2 (1996) 883-888
13. Sato T., Tanigami A., Yamakawa K., et al. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 50 (1990) 7184-7189
14. Varley J.M., Brammar W.J., Lane D.P., Swallow J.E., Dolan C., and Walker R.A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6 (1991) 413-421
15. Sigurdsson S., Bodvarsdottir S.K., Anamthawat-Jonsson K., et al. p53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genet Cytogenet 121 (2000) 150-155
16. Jarvinen T.A., and Liu E.T. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 78 (2003) 299-311
17. Jarvinen T.A., and Liu E.T. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology 14 (2003) 309-313
18. Jarvinen T.A., Tanner M., Barlund M., Borg A., and Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26 (1999) 142-150
19. Beser A.R., Tuzlali S., Guzey D., Dolek Guler S., Hacihanefioglu S., and Dalay N. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 13 (2007) 180-185
20. Bofin A.M., Ytterhus B., and Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14 (2003) 314-319
21. Slamon D, Eiermann W, Robert Nm et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in ERBB2neu positive early breast cancer patients. San Antonio Breast Cancer Seminar; San Antonio, TX, USA; Dec 14-17, 2006.
22. Arriola E., Rodriguez-Pinilla S.M., Lambros M.B., et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in ERBB2 positive early breast cancer. Breast Cancer Res Treat 106 (2007) 181-189
23. Perez E., Romond E., Suman V., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with ERBB2-positive breast cancer. J Clin Oncol 25 suppl (2007) 512
24. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable ERBB2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
25. Hofmann M., Stoss O., Gaiser T., et al. Central ERBB2 IHC and FISH analysis in a trastuzumab (Herceptin(R)) Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 1 (2007) 89-94
26. Kaufman P.A., Broadwater G., Lezon-Geyda K., et al. CALGB 150002: correlation of ERBB2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in ERBB2+ and ERBB2- metastatic breast cancer (MBC). J Clin Oncol 25 (2007) 1009
27. Risio M., Casorzo L., Redana S., and Montemurro F. ERBB2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep 13 (2005) 305-309
28. Reinholz M., Jenkins R.B., Hillman D., et al. The clinical significance of polysomy 17 in the ERBB2+ N9831 intergroup adjuvant trastuzumab trial. Breast Cancer Res Treat 106 supp 1 (2007) 11
29. Herrington C.S., Leek R.D., and McGee J.O. Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. J Pathol 176 (1995) 353-359
30. Ichikawa D., Hashimoto N., Hoshima M., et al. Analysis of numerical aberrations in specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer 77 (1996) 2064-2069
31. McManus D.T., Patterson A.H., Maxwell P., et al. Interphase cytogenetics of chromosomes 11 and 17 in fine needle aspirates of breast cancer. Hum Pathol 30 (1999) 137-144
32. Tsukamoto F., Miyoshi Y., Egawa C., et al. Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 93 (2001) 165-170
33. Fehm T., Morrison L., Saboorian H., Hynan L., Tucker T., and Uhr J. Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors. Breast Cancer Res Treat 75 (2002) 227-239
34. Nakopoulou L., Giannopoulou I., Trafalis D., Gakiopoulou H., Keramopoulos A., and Davaris P. Evaluation of numeric alterations of chromosomes 1 and 17 by in situ hybridization in invasive breast carcinoma with clinicopathologic parameters. Appl Immunohistochem Mol Morphol 10 (2002) 20-28
35. Wang S., Saboorian M.H., Frenkel E.P., et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15 (2002) 137-145
36. Watters A.D., Going J.J., Cooke T.G., and Bartlett J.M. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77 (2003) 109-114
37. Ma Y., Lespagnard L., Durbecq V., et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11 (2005) 4393-4399
38. Merola R., Mottolese M., Orlandi G., et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 42 (2006) 1501-1506
39. Takehisa M., Sasa M., Bando Y., et al. Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer. Anticancer Res 27 (2007) 1073-1078
40. Hyun C.L., Lee H.E., Kim K.S., et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 61 (2008) 317-321
41. Mezzelani A., Alasio L., Bartoli C., et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 80 (1999) 519-525
42. Farabegoli F., Ceccarelli C., Santini D., et al. c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. Int J Cancer 84 (1999) 273-277
43. Jimenez R.E., Wallis T., Tabasczka P., and Visscher D.W. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13 (2000) 37-45
44. Bose S., Mohammed M., Shintaku P., and Rao P.N. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 7 (2001) 337-344
45. Tubbs R.R., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., and Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19 (2001) 2714-2721
46. Varshney D., Zhou Y.Y., Geller S.A., and Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 121 (2004) 70-77
47. Salido M., Tusquets I., Corominas J.M., et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 7 (2005) 267-273
48. Downs-Kelly E., Yoder B.J., Stoler M., et al. The influence of polysomy 17 on ERBB2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29 (2005) 1221-1227
49. Torrisi R., Rotmensz N., Bagnardi V., et al. ERBB2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43 (2007) 2339-2344
50. Vanden Bempt I., Van Loo P., Drijkoningen M., et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26 (2008) 4869-4874
51. Visscher D., Jimenez R.E., Grayson M., Mendelin J., and Wallis T. Histopathologic analysis of chromosome aneuploidy in ductal carcinoma in situ. Hum Pathol 31 (2000) 201-207
52. McManus D.T., Patterson A.H., Maxwell P., Humphreys M.W., and Anderson N.H. Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates. Mol Pathol 52 (1999) 75-77
53. Schmitt F.C., Soares R., and Leitao D. Detection of numerical chromosome 17 abnormalities in fine-needle aspirates of breast cancer using a novel in situ hybridization signal amplification method. Diagn Cytopathol 19 (1998) 141-146
54. Murphy D.S., McHardy P., Coutts J., et al. Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 64 (1995) 18-26
55. Marinho A.F., Botelho M., and Schmitt F.C. Evaluation of numerical abnormalities of chromosomes 1 and 17 in proliferative epithelial breast lesions using fluorescence in situ hybridization. Pathol Res Pract 196 (2000) 227-233
56. Micale M.A., Visscher D.W., Gulino S.E., and Wolman S.R. Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 25 (1994) 29-35
57. Visscher D.W., Wallis T.L., and Crissman J.D. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics. Cancer 77 (1996) 315-320
58. Mendelin J., Grayson M., Wallis T., and Visscher D.W. Analysis of chromosome aneuploidy in breast carcinoma progression by using fluorescence in situ hybridization. Lab Invest 79 (1999) 387-393
59. Sneige N., Liu B., Yin G., Gong Y., and Arun B.K. Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol 19 (2006) 622-629
60. Murphy D.S., Hoare S.F., Going J.J., et al. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst 87 (1995) 1694-1704
61. Lal P., Salazar P.A., Ladanyi M., and Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 5 (2003) 155-159
62. McCormick S.R., Lillemoe T.J., Beneke J., Schrauth J., and Reinartz J. ERBB2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 117 (2002) 935-943
63. Lamy P.J., Nanni I., Fina F., et al. Reliability and discriminant validity of ERBB2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 21 (2006) 20-29
64. Dal Lago L., Durbecq V., Desmedt C., et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5 (2006) 2572-2579
65. Corzo C., Bellosillo B., Corominas J.M., et al. Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis. Tumour Biol 28 (2007) 221-228
66. Vanden Bempt I., Vanhentenrijk V., Drijkoningen M., Wlodarska I., Vandenberghe P., and De Wolf-Peeters C. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology 46 (2005) 431-441
67. Zhao J., Wu R., Au A., Marquez A., Yu Y., and Shi Z. Determination of ERBB2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 15 (2002) 657-665
68. Vanden Bempt I., Drijkoningen M., Van Loo P., et al. HER-2 gene amplification but not chromosome 17 polysomy defines a distinct breast cancer phenotype. Breast Disease 25 (2006) 45
69. Adeyinka A., Mertens F., Idvall I., Bondeson L., and Pandis N. Multiple polysomies in breast carcinomas: preferential gain of chromosomes 1, 5, 6, 7, 12, 16, 17, 18, and 19. Cancer Genet Cytogenet 111 (1999) 144-148
70. Chen T., Dhingra K., Sahin A., Sneige N., Hortobagyi G., and Aldaz C.M. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Res Treat 39 (1996) 177-185
71. Vanden Bempt I., Drijkoningen M., and De Wolf-Peeters C. The complexity of genotypic alterations underlying ERBB2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 19 (2007) 552-557
72. Di Leo A., Gomez H.L., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26 (2008) 5542-5552
73. Livingston R.B., Downey L., Di Leo A., et al. Evaluation of chromosome 17 (Chr-17) polysomy in ERBB2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib. J Clin Oncol 26 suppl (2008) abstr 1006.
74. Weaver B.A., Silk A.D., Montagna C., Verdier-Pinard P., and Cleveland D.W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11 (2007) 25-36
75. Walker R.A., Bartlett J., Dowsett M., et al. ERBB2 testing in the UK-further update to recommendations. J Clin Pathol 61 (2008) 818-824
76. Rosenberg C.L. Polysomy 17 and HER-2 Amplification: true, true, and unrelated. J Clin Oncol 26 (2008) 4856-4858